Exelixis stock sits 1.83 percent below its 52-week high on October 16

Published on 10/17/2026 at 21:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

2026 revenue guidance is USD 2.50-2.55 billion, issued August 5, 2026. Exelixis stock was last at EUR 55.36 on October 16, 2026.

Valuation and analyst signals

On October 16, 2026, the Nasdaq quote placed Exelixis stock 1.83 percent below its 52-week high.
RBC Capital lifted its target from USD 45.00 to USD 51.00 on October 9, 2026.
Exelixis stock was last at EUR 55.36 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST.
Exelixis carried a P/E ratio of 19.51 and a market capitalization of USD 15.6 billion.

EXEL, US30161Q1040, Illustration mit AI erstellt.

Exelixis stock stood 1.83 percent below its 52-week high on October 16, 2026, when its Nasdaq quote was last at USD 62.23. Markets Insider reported that RBC Capital raised its target from USD 45.00 to USD 51.00 on October 9, 2026. The last euro quote was EUR 55.36 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST.

Guidance sets the earnings frame

Exelixis entered the second half of 2026 with a total revenue guidance range of USD 2.50 billion to USD 2.55 billion. The range was issued in the company's August 5, 2026 results release, which also identified USD 2.30 billion to USD 2.35 billion as the expected net product revenue range. The guidance excludes potential revenue from a future US approval and launch of zanzalintinib for colorectal cancer, keeping the regulatory outcome separate from the current operating forecast.

Stock remains near its yearly high

The Nasdaq quote was last at USD 62.23 on October 16, 2026 at 4:00 p.m. ET, down USD 0.60, or 0.95 percent, from USD 62.83. The session range was USD 61.75 to USD 63.39, while volume reached 2,005,403 shares against an average of 2,375,665. The 52-week range was USD 33.76 to USD 63.39, leaving the stock 1.83 percent below its high.

Valuation carries a mixed signal

Exelixis had a market capitalization of USD 15.6 billion and a P/E ratio of 19.51 on October 16, 2026. The home-market quote also carried a 0.04 dividend yield. RBC's USD 51.00 target sits 18.05 percent below the USD 62.23 Nasdaq quote, a concrete counterpoint to the stock's position near its yearly high.

Comparison with peers

Exelixis (Nasdaq, USD): minus 0.95 percent, P/E 19.51, market capitalization USD 15.6 billion.
Bristol-Myers Squibb (NYSE, USD): minus 1.35 percent, P/E 13.16, market capitalization USD 122.1 billion.
Incyte (Nasdaq, USD): minus 0.18 percent, P/E 14.40, market capitalization USD 22.9 billion.

Euro quote remains dated

The euro quotation places Exelixis at EUR 55.36 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST. The Nasdaq quote was last at USD 62.23 on October 16, 2026 at 4:00 p.m. ET, giving investors in Germany a separate view of the same session.

The further course of trading is shown by the continuously updated real-time quote of Exelixis stock.